GLP-1 drugs: strong weight loss but limited quality of life gains, study finds

A major meta-analysis of 262 trials with nearly 100,000 participants found that while GLP-1 drugs like Ozempic and Mounjaro produce substantial weight loss, they do not significantly improve quality of life and most show no convincing cardiovascular benefits after one year. Source: El Confidencial, Euronews, Infobae, El Mundo

Key findings from the meta-analysis

• Tirzepatide (Mounjaro) and CagriSema produced the greatest weight loss (14.9% and 14.8% respectively) Source: El Mundo, Infobae.
• Greater weight loss was consistently associated with higher rates of adverse events and treatment discontinuation Source: Euronews, El Mundo.
• Only subcutaneous semaglutide (Ozempic, Wegovy) showed reductions in all-cause mortality (19%), myocardial infarction (28%), and heart failure (57%) Source: El Confidencial, Infobae.
• No drug convincingly reduced renal failure or showed clinically important improvements in quality of life Source: El Confidencial, Infobae.

Conflicting evidence and context

While the BMJ study tempers expectations, other research suggests potential benefits: a meta-analysis of 4 million patients found GLP-1 drugs reduced obesity-related cancer risk by 30% Source: La Voz, and a study in non-diabetic patients showed a 41% reduction Source: La Voz. However, causality remains unproven Source: La Voz.

Experts emphasize that weight loss alone does not guarantee better health. "La báscula cuenta parte de la historia, pero no toda" says José M. Ordovás Source: Infobae. Upon stopping, patients often regain weight: studies show an average recovery of two-thirds of lost weight within a year if lifestyle habits are not changed Source: Diario Libre. The diariolibree article underscores that preserving muscle mass and adopting sustainable habits are crucial to avoid the rebound effect.